Veracyte in the news
November 6, 2024
Veracyte Further Cements Data on Core Prostate Test as Q3 Revenues Climb 29 Percent
GenomeWeb
October 31, 2024
Genetic Test Predicts Survival Benefit From Docetaxel in Prostate Cancer
Oncology Times
October 2, 2024
Veracyte’s RNA Genetic Test Predicts Black Men’s Aggressive Prostate Cancer
Inside Precision Medicine
September 29, 2024
The Future is Bright for Veracyte and Molecular Diagnostics
OPTO
September 25, 2024
The Care Continuum: Veracyte’s CEO on its Diagnostic Strategy
OPTO
September 14, 2024
Gerhard Attard, MD, on the interaction between Decipher score and docetaxel benefit
Urology Times
September 14, 2024
Veracyte’s CEO talks about ESMO data from it’s prostate cancer diagnostic that could change how metatstatic prostate cancer is treated
BiotechTV